AGN Media thread, page-273

Mate what repeat. I have explained the obvious in this drug class. AGN has been in development for 10 years. This is a drug peptide that was developed during the rush into due to the neuroprotective nature of this drug class which multiple other companies have developed. The results tell you the peptide in human brains in phase 3 in thousands of patients produced an anomaly in the findings. This was a hit to AGN because when they listed back in 2020 its was all about them being longer acting hence getting a better response. But that doesn’t matter because the previous peptides didn’t work even after being continually infused over 3 days.

Im simply telling you based on drug class we already know the outcome of safety, mechanism of action and can extrapolate efficacy based off previous results. AGN was flawed once NA-1 and others began to fail in 2022-2023 it’s why the share price fell to 20 cents a share during that time. I hold a significant parcel because it’s can easily be predicted what phase 2 will produce from pretty much the same drugs tested before